Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

Resuscitec selected to be one of the ‘Top 10 MedTech Startups in Europe 2023’

‘MedTech Outlook’ is an international medical technology magazine with over 132,300 subscribers across Europe. Each year, the European edition of the magazine shortlists 10 companies to be part of the ‘Top 10 MedTech Startups in Europe’.

The upcoming 4th annual issue of the magazine will feature the ‘Top 10 MedTech Startups in Europe 2023’.

Initially, subscribers are asked to nominate MedTech startups that they think are about to offer new solutions to existing problems in the MedTech sector.

Afterwards MedTech Outlook reviews the nominated companies and short-lists them. Various factors are considered, such as their website, industry experience and news as well as client testimonials and surveys of potential buyers.

The final decision is then made by an evaluation panel composed of the Senior Editorial Team and buyers of MedTech Startup services.

This year Resuscitec was among the chosen ones and will be featured in the upcoming December issue as one of the ‘Top 10 MedTech Startups in Europe’.

Certificate MEDTECH OUTLOOK - Top 10 MedTech Startups in Europe 2023

Magazine article